With many promising novel therapeutic agents exiting pharmaceutical pipelines, a question that arises is whether standard chemotherapy regimens with long-term data should be shunned or altered in favor of newer small molecule inhibitors. In this insightful interview, Susan OBrien, MD, of the University of California, Irvine, CA, discusses the Phase II study of ibrutinib, fludarabine, cyclophosphamide and obinutuzumab (iFCG) as a first-line treatment for patients with IGHV-mutated chronic lymphocytic leukemia (CLL). Prof. OBrien highlights the reasoning behind the agents combined in this study, and what the results of the study tell us and how they may inform future studies. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Should standard chemotherapy regimens be altered in favor of small molecules? iFCG for frontline CLL
